The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model
Open accessAbstract
Disablement of cell death programs in cancer cells contributes to drug resistance and in some cases has been associated with altered translational control. As eukaryotic translation initiation factor 4E (eIF4E) cooperates with c-Myc during lymphomagenesis, induces drug resistance, and is a genetic modifier of the rapamycin response, we have investigated the effect of dysregulation of the ribosome recruitment phase of translation initiation on tumor progression and chemosensitivity. eIF4E is a subunit of eIF4F, a complex that stimulates ribosome recruitment during translation initiation by delivering the DEAD-box RNA helicase eIF4A to the 5' end of mRNAs. eIF4A is thought to prepare a ribosome landing pad on mRNA templates for incoming 40S ribosomes (and associated factors). Using small molecule screening, we found that cyclopenta[b]benzofuran flavaglines, a class of natural products, modulate eIF4A activity and inhibit translation initiation. One member of this class of compounds, silvestrol, was able to enhance chemosensitivity in a mouse lymphoma model in which carcinogenesis is driven by phosphatase and tensin homolog (PTEN) inactivation or elevated eIF4E levels. These results establish that targeting translation initiation can restore drug sensitivity in vivo and provide an approach to modulating chemosensitivity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
Current development of mTOR inhibitors as anticancer agents
Faivre, S., Kroemer, G., & Raymond, E. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2062 · Cited by 1,000
Jurica, M. S., & Moore, M. J. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00270-3 · Cited by 962
Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap
Lazaris-Karatzas, A., Montine, K. S., & Sonenberg, N. (1990) · Nature · doi:10.1038/345544a0 · Cited by 956
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy
Wendel, H.-G., Stanchina, E. D., Fridman, J. S., Malina, A., Ray, S., Kogan, S., Cordon-Cardo, C., Pelletier, J., & Lowe, S. W. (2004) · Nature · doi:10.1038/nature02369 · Cited by 951
Self-citationDEAD-box proteins: the driving forces behind RNA metabolism
Rocak, S., & Linder, P. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1335 · Cited by 772
Molecular mechanisms of translation initiation in eukaryotes
Pestova, T. V., Kolupaeva, V. G., Lomakin, I. B., Pilipenko, E. V., Shatsky, I. N., Agol, V. I., & Hellen, C. U. T. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.111145798 · Cited by 742
S6K1- and ßTRCP-Mediated Degradation of PDCD4 Promotes Protein Translation and Cell Growth
Dorrello, N. V., Peschiaroli, A., Guardavaccaro, D., Colburn, N. H., Sherman, N. E., & Pagano, M. (2006) · Science · doi:10.1126/science.1130276 · Cited by 731
Research works printed but not linked: 11
- Raught, B., Gingras, A.-C., and Sonenberg, N. 2000.Regulation of ribosome recruitment in eukaryotes. Cold Spring Harbor Laboratory Press. Cold Spring Harbor, New York, USA. 245–293.
- Fukuchi-Shimogori, 1997, Cancer Res., 57, 5041
- Rousseau, 1996, Oncogene., 13, 2415
- De Benedetti, 1991, Mol. Cell. Biol., 11, 5435, 10.1128/MCB.11.11.5435 · doi:10.1128/mcb.11.11.5435
- 10.1021/np060428x · doi:10.1021/np060428x
- Mi, 2006, Anticancer Res., 26, 947
- Mi, 2006, Anticancer Res., 26, 3349
- Shuda, 2000, Anticancer Res., 20, 2489
- 10.1016/S1357-2725(00)00007-8 · doi:10.1016/s1357-2725(00)00007-8
- Kim, 2007, Anticancer Res., 27, 2175
- 10.1016/S0031-9422(00)00471-4 · doi:10.1016/s0031-9422(00)00471-4
Cited by
Functional 5′ UTR mRNA structures in eukaryotic translation regulation and how to find them
Leppek, K., Das, R., & Barna, M. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.103 · Cited by 949
Translational control in cancer
Silvera, D., Formenti, S. C., & Schneider, R. J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2824 · Cited by 821
Targeting the translation machinery in cancer
Bhat, M., Robichaud, N., Hulea, L., Sonenberg, N., Pelletier, J., & Topisirovic, I. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4505 · Cited by 799
Self-citationRNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer
Wolfe, A. L., Singh, K., Zhong, Y., Drewe, P., Rajasekhar, V. K., Sanghvi, V. R., Mavrakis, K. J., Jiang, M., Roderick, J. E., Van der Meulen, J., et al. (2014) · Nature · doi:10.1038/nature13485 · Cited by 635
Self-citationFor better or for worse: the role of Pim oncogenes in tumorigenesis
Nawijn, M. C., Alendar, A., & Berns, A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2986 · Cited by 481
Stress granules, P-bodies and cancer
Anderson, P., Kedersha, N., & Ivanov, P. (2015) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.11.009 · Cited by 409
New frontiers in translational control of the cancer genome
Truitt, M. L., & Ruggero, D. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.27 · Cited by 378
Mechanistic insights into mammalian stress granule dynamics
Panas, M. D., Ivanov, P., & Anderson, P. (2016) · Journal of Cell Biology · doi:10.1083/jcb.201609081 · Cited by 374
eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies
Boussemart, L., Malka-Mahieu, H., Girault, I., Allard, D., Hemmingsson, O., Tomasic, G., Thomas, M., Basmadjian, C., Ribeiro, N., Thuaud, F., et al. (2014) · Nature · doi:10.1038/nature13572 · Cited by 371
Targeting the eIF4F Translation Initiation Complex: A Critical Nexus for Cancer Development
Pelletier, J., Graff, J., Ruggero, D., & Sonenberg, N. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2789 · Cited by 367
Self-citationMammalian stress granules and P bodies at a glance
Riggs, C. L., Kedersha, N., Ivanov, P., & Anderson, P. (2020) · Journal of Cell Science · doi:10.1242/jcs.242487 · Cited by 367
Rocaglates convert DEAD-box protein eIF4A into a sequence-selective translational repressor
Iwasaki, S., Floor, S. N., & Ingolia, N. T. (2016) · Nature · doi:10.1038/nature17978 · Cited by 313
Erratum: New frontiers in translational control of the cancer genome
Truitt, M. L., & Ruggero, D. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.30 · Cited by 303
Antitumor Activity and Mechanism of Action of the Cyclopenta[b]benzofuran, Silvestrol
Cencic, R., Carrier, M., Galicia-Vázquez, G., Bordeleau, M.-E., Sukarieh, R., Bourdeau, A., Brem, B., Teodoro, J. G., Greger, H., Tremblay, M. L., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005223 · Cited by 302
Self-citationTight Coordination of Protein Translation and HSF1 Activation Supports the Anabolic Malignant State
Santagata, S., Mendillo, M. L., Tang, Y.-C., Subramanian, A., Perley, C. C., Roche, S. P., Wong, B., Narayan, R., Kwon, H., Koeva, M., et al. (2013) · Science · doi:10.1126/science.1238303 · Cited by 285
Self-citationDrug resistance in cancer: mechanisms and tackling strategies
Haider, T., Pandey, V., Banjare, N., Gupta, P. N., & Soni, V. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00138-7 · Cited by 282
The Relevance of Higher Plants in Lead Compound Discovery Programs
Kinghorn, A. D., Pan, L., Fletcher, J. N., & Chai, H. (2011) · Journal of Natural Products · doi:10.1021/np200391c · Cited by 282
Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy
Steelman, L. S., Franklin, R. A., Abrams, S. L., Chappell, W., Kempf, C. R., Bäsecke, J., Stivala, F., Donia, M., Fagone, P., Nicoletti, F., et al. (2011) · Leukemia · doi:10.1038/leu.2011.66 · Cited by 261
Translational control of tumor immune escape via the eIF4F–STAT1–PD-L1 axis in melanoma
Cerezo, M., Guemiri, R., Druillennec, S., Girault, I., Malka-Mahieu, H., Shen, S., Allard, D., Martineau, S., Welsch, C., Agoussi, S., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0217-1 · Cited by 254
Rubio, C. A., Weisburd, B., Holderfield, M., Arias, C., Fang, E., DeRisi, J. L., & Fanidi, A. (2014) · Genome Biology · doi:10.1186/s13059-014-0476-1 · Cited by 200
“This compound has been shown to selectively target the RNA helicase activity of eIF4A both in vitro and in vivo, thereby impairing translation initiation [21,22], and is known to have robust anti-cancer effects [23,24].”
BackgroundHashimoto, S., Furukawa, S., Hashimoto, A., Tsutaho, A., Fukao, A., Sakamura, Y., Parajuli, G., Onodera, Y., Otsuka, Y., Handa, H., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1901765116 · Cited by 149
Schatz, J. H., Oricchio, E., Wolfe, A. L., Jiang, M., Linkov, I., Maragulia, J., Shi, W., Zhang, Z., Rajasekhar, V. K., Pagano, N. C., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110846 · Cited by 119
Self-citationMolecular Pathways: The eIF4F Translation Initiation Complex—New Opportunities for Cancer Treatment
Malka-Mahieu, H., Newman, M., Désaubry, L., Robert, C., & Vagner, S. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2362 · Cited by 105
Rodrigo, C. M., Cencic, R., Roche, S. P., Pelletier, J., & Porco, J. A. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201263k · Cited by 99
Self-citation(2024) · doi:10.1038/s41594-023-01196-0 · Cited by 92
Altering chemosensitivity by modulating translation elongation
Robert, F., Carrier, M., Rawe, S., Chen, S., Lowe, S., & Pelletier, J. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005428 · Cited by 90
Self-citationGupta, S. V., Sass, E. J., Davis, M. E., Edwards, R. B., Lozanski, G., Heerema, N. A., Lehman, A., Zhang, X., Jarjoura, D., Byrd, J. C., et al. (2011) · The AAPS Journal · doi:10.1208/s12248-011-9276-7 · Cited by 81
Amidino-Rocaglates: A Potent Class of eIF4A Inhibitors
Chu, J., Zhang, W., Cencic, R., Devine, W. G., Beglov, D., Henkel, T., Brown, L. E., Vajda, S., Porco, J. A., & Pelletier, J. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.08.008 · Cited by 74
Self-citationTargeting Translation of mRNA as a Therapeutic Strategy in Cancer
Pal, I., Safari, M., Jovanovic, M., Bates, S. E., & Deng, C. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-00530-y · Cited by 46
Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
Singh, K., Lin, J., Lecomte, N., Mohan, P., Gokce, A., Sanghvi, V. R., Jiang, M., Grbovic-Huezo, O., Burčul, A., Stark, S. G., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2929 · Cited by 39
Self-citationTranslation Inhibitors Activate Autophagy Master Regulators TFEB and TFE3
Dang, T. T., & Back, S. H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222112083 · Cited by 33
Zhao, N., Kabotyanski, E. B., Saltzman, A. B., Malovannaya, A., Yuan, X., Reineke, L. C., Lieu, N., Gao, Y., Pedroza, D. A., Calderon, S. J., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci172503 · Cited by 30
NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy
Sanghvi, V. R., Mohan, P., Singh, K., Cao, L., Berishaj, M., Wolfe, A. L., Schatz, J. H., Lailler, N., de Stanchina, E., Viale, A., et al. (2021) · Cancers · doi:10.3390/cancers13040639 · Cited by 27
“more modestly against pancreatic cancer [21,34,35].”
Self-citationSénéchal, P., Robert, F., Cencic, R., Yanagiya, A., Chu, J., Sonenberg, N., Paquet, M., & Pelletier, J. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03940-5 · Cited by 20
Self-citationAssociation of ribosomal protein S6 kinase 1 with cellular radiosensitivity of non-small lung cancer
Wang, Y., Mei, H., Shao, Q., Wang, J., & Lin, Z. (2017) · International Journal of Radiation Biology · doi:10.1080/09553002.2017.1294273 · Cited by 10
Metadata
- Authors
- Bordeleau, M.-E., Robert, F., Gerard, B., Lindqvist, L., Chen, S. M. H., Wendel, H.-G., Brem, B., Greger, H., Lowe, S. W., Porco, J. A., & Pelletier, J.
- Venue
- Journal of Clinical Investigation
- Published
- 2008-06-01
- Volume
- 118
- Issue
- 7
- Pages
- 2651-60
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2030802073
- Cited by
- 332
- References
- 63
- FWCI
- 6.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.